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Abstract
Significance: Current guidelines for rheumatoid arthritis (RA) management recommend early treatment with
disease modifying antirheumatic drugs (DMARDs). However, DMARD treatment fails in 30% of patients and
current monitoring methods can only detect failure after 3 to 6 months of therapy.
Aim: We investigated whether joint blood flow (BF), quantified using dynamic contrast-enhanced time-resolved
near-infrared spectroscopy, can monitor disease activity and treatment response in a rat model of RA.
Approach: Ankle joint BF was measured every 5 days in eight rats with adjuvant-induced arthritis (AIA) and four
healthy controls. Arthritis was allowed to progress for 20 days before rats with AIA were treated with a DMARD
once every 5 days until day 40.
Results: Time and group had separate significant main effects on joint BF; however, there was no significant
interaction between time and group despite a notable difference in average joint BF on day 5. Comparison of
individual blood flow measures between rats with AIA and control group animals did not reveal a clear response
to treatment.
Conclusions: Joint BF time courses could not distinguish between rats with AIA and study controls.
Heterogeneous disease response and low temporal frequency of BF measurements may have been important
study limitations.
© The Authors. Published by SPIE under a Creative Commons Attribution 4.0 Unported License. Distribution or reproduction of this work in whole or in
part requires full attribution of the original publication, including its DOI. [DOI: 10.1117/1.JBO.25.1.015003]
Keywords: time-resolved near-infrared spectroscopy; dynamic contrast-enhanced; blood flow; rheumatoid arthritis; treatment mon-
itoring; disease-modifying antirheumatic drugs.
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1 Introduction
Rheumatoid arthritis (RA) is a chronic and progressive auto-
immune disease that afflicts about 1% of the population and is
associated with pain,1 reduced quality of life,2 and disability.3
Fortunately, the introduction of a treatment paradigm that
combines treat-to-target strategies4 with early use of disease-
modifying antirheumatic drugs (DMARDs)5 has significantly
improved mid- and long-term patient outcomes over the past
two decades. However, DMARD treatment failure, which is cur-
rently identified only after 3 to 6 months of therapy, still occurs
in 30% of RA patients.6,7 After failure, these patients must
undergo an iterative process where they are assigned to new
therapies and wait again for 3 to 6 months before treatment effi-
cacy can be reliably assessed. This process is drawn-out, costly,
and results in patients losing the benefits of effective early treat-
ment while having an increased risk of developing irreversible
joint damage.8
Treatment response is currently assessed using a combina-
tion of clinical examination and patient self-assessment. Though
this approach is the current standard of care, it can be ineffective
for repetitive, longitudinal assessments because of its subjec-
tivity and variability.9,10 Furthermore, clinical examination and
patient self-assessment are unlikely to detect subclinical
changes in inflammation, which could be early indications of
treatment response. As such, clinical examination is often sup-
plemented with laboratory tests, radiography, or ultrasonogra-
phy. However, though these additional tools can be effective
at aiding diagnosis, their usefulness for long-term monitoring
is limited by low sensitivity (radiography and laboratory
tests)11 and suboptimal reproducibility (ultrasonography).12–14
Given the above limitations, there is currently a need to find
more sensitive and objective techniques that can detect RA treat-
ment failure within the first 3 months of therapy.
In recent years, there has been a growing interest in inves-
tigating the ability of near-infrared (NIR) optical methods to
assess RA disease progression. This is in part due to the ability
of NIR techniques to provide quick and objective measurements
at a relatively low cost. In the case of RA, NIR methods*Address all correspondence to Mamadou Diop, E-mail: mdiop@uwo.ca
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generally attempt to monitor disease progression by measuring
downstream effects of joint hypoxia, which is well known to
play a central role in the maintenance and progression of the
disease.15,16 It is well established that chronic inflammation,
which is a key feature of RA, causes hypertrophy of the synovial
lining; the thickness of the synovial membrane increases from
1 to 3 to over a dozen cell layers in RA.16 This hypertrophic cell
mass induces an increased metabolic demand that exceeds sup-
ply, leading to the development of hypoxic regions within the
synovium.15,17 In fact, it has been shown (using invasive probes)
that the partial pressure of oxygen is lower in inflamed joints
than in healthy joints.18 The presence of chronic hypoxia then
acts as a signal both for the formation of new blood vessels
(i.e., angiogenesis)17 and increased tissue blood flow (BF).19,20
Previous studies using NIR techniques have largely focused
on assessing changes in oxygen saturation and blood content
within the joint since these characterize hypoxia and angiogen-
esis, respectively, and are the downstream effects of chronic
inflammation. Some examples of NIR techniques that have been
applied to RA disease monitoring include photoacoustic tomog-
raphy,21–24 diffuse optical spectroscopy,25–27 contrast-based fluo-
rescence imaging,28–30 and diffuse optical tomography.31–34
Using these approaches, RA disease progression can be assessed
by measuring increases in blood volume, variations in blood
oxygen saturation, intensity of contrast agent fluorescence, and
total hemoglobin concentration in the joint. As mentioned,
increased tissue BF—defined as the volume of blood flowing
through a mass of tissue per unit time (mL/min/100 g)—is
another physiological response to chronic hypoxia; in fact, joint
BF has yet to be thoroughly investigated as a potentially highly
sensitive marker of RA disease activity. Thus, we hypothesized
that BF can be a surrogate marker of changes in joint hypoxia
and RA disease progression. We previously developed a
dynamic contrast-enhanced time-resolved near-infrared spec-
troscopy (DCE TR-NIRS) technique for measuring joint BF and
showed—in a rabbit model of RA—that joint BF is more sen-
sitive to inflammatory arthritis than changes in hemoglobin con-
centration and oxygen saturation.35 These findings suggest that
joint BF may be a more sensitive biomarker of inflammatory
arthropathies than those previously investigated with other
NIR techniques. Thus, the objective of this work was to inves-
tigate whether joint BF, as measured with DCE TR-NIRS, can
track longitudinal changes in joint inflammation during disease
induction and DMARD treatment in a rat model of RA.
2 Methods
2.1 Instrumentation
The TR-NIRS system was built in-house using a pulsed diode
laser (LDH-P-C-810; PicoQuant, Germany) connected to a PDL
828 laser driver (PicoQuant). The laser emission was centered at
805 nm and the pulse repetition rate was set to 80 MHz. The
laser output was coupled into an emission fiber (ϕ ¼ 400 μm,
NA ¼ 0.22; Fiberoptics Technology, Pomfret, Connecticut) that
guided light to the ankle joint. Light transmitted through the
ankle joint was collected with a fiber optic bundle (ϕ ¼ 3 mm,
NA ¼ 0.55; Fiberoptics Technology) that was coupled to a
hybrid photomultiplier detector (PMA Hybrid; PicoQuant) and
a time-correlated single photon-counting module (HydraHarp
400; PicoQuant). A three-dimensional (3-D)-printed probe-
holder was used to ensure good contact between the ankle joint
and the emission and detection probes. Instrument response
functions (IRFs) were acquired by placing the emission and
detection probes into a light-tight box containing a piece of
paper, positioned 2 mm away from the emission fiber, which
acted as a light diffuser to fill the numerical aperture of the
detection probe.
2.2 Phantom Experiments
Since the DCE TR-NIRS technique relies on accurate estimation
of changes in tissue absorption, we assessed the system’s
ability to measure absorption changes in a tissue-mimicking
phantom made with Intralipid and India Ink. A cuvette
(10 mm × 10 mm × 40 mm) was filled with 3.5 mL of 0.8%
Intralipid created by diluting a 20% stock solution of Intralipid
with water. We then placed the emission and detection probes
transversely across the cuvette, secured the entire setup using a
3-D-printed holder, and acquired a baseline measurement with
the TR-NIRS system. Next, we began adding 0.02-mL incre-
ments of an India Ink solution with a known absorption coef-
ficient (μa;ink). Note that μa;ink was determined by measuring
light transmittance through an India ink dilution to determine
the ink’s molar absorption coefficient (see Sec. 2.4 for details).
The volume of increments was chosen so that the investigated
changes in absorption would cover a range similar to what had
been measured during preliminary animal experiments (0.005 to
0.040 cm−1). After adding each 0.02-mL increment, the solu-
tion was mixed with a glass stirring rod and left to settle for
60 s before the next set of measurements. Each set of TR-
NIRS measurements consisted of 100 distributions of time-
of-flight (DTOFs) acquired over 30 s.
2.3 Animal Model and Experiments
Animal experiments were conducted under an animal care pro-
tocol approved by the local ethics committee. All experimental
procedures were conducted while the animals were under anes-
thetic. Anesthesia was induced in an airtight chamber with 5%
isoflurane gas and maintained with 2% isoflurane by mask.
The study included 12 adult male Lewis rats: four rats in the
control group and eight rats in the experimental group (exper-
imental timeline is shown in Fig. 1). Arthritis was induced using
the adjuvant-induced arthritis (AIA) model.36 Prior to the start of
the study, animals were allowed to acclimate for 5 to 7 days,
after which three baseline BF measurements were acquired over
a 10-day period (Fig. 1). After the third baseline measurement
was acquired on day 0, rats in the experimental group received a
subcutaneous injection of a solution prepared using heat-killed
lyophilized Mycobacteria butyricum suspended in incomplete
Freund’s adjuvant to induce polyarticular arthritis;37 rats in the
control group received saline injections. Thereafter, ankle joint
BF was measured every 5 days until the end of the study on day
40 or until rats reached predetermined humane endpoints (HEP)
based on pain assessment by a veterinarian. AIAwas allowed to
progress until day 20 (pretreatment phase). Starting on day 20,
the treatment phase of the study began: rats that had not reached
HEP were treated with intramuscular injections of the DMARD
etanercept (Enbrel®: 0.5 mL/kg) every 5 days. Treatments were
administered on each measurement day within the treatment
phase immediately after BF measurements. Rats in the experi-
mental group were studied in separate cohorts of 2; the entire
study protocol (e.g., induction, treatment) was repeated four
times with cohorts of 2 rats for a final sample size of 8 in the
experimental group. Rats in the control group were studied
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simultaneously in one cohort of four animals. Weight measure-
ments and qualitative written notes describing animal appear-
ance, behavior, gait, and swelling in the paws or joints were
recorded for each rat on and between study days by two certified
veterinary technicians (L. Morrison and L. Desjardins). These
observations were used in consultation with a veterinarian to
determine the appearance of first symptoms of induced inflam-
mation and to assess whether an animal had reached HEP.
Evidence of arthritis included visible swelling in paws or joints,
weight loss (>5% of initial body weight), reluctance to ambu-
late, decreased social interaction, and abnormal posture.
The experimental setup for the BF measurements is shown in
Fig. 2. During each measurement, animals received a tail vein
bolus injection of the optical contrast agent Indocyanine Green
(ICG). A dye densitometer (DDG-2001; Nihon Kohden, Japan)
was attached to one paw to measure the arterial concentration
of ICG. The dye densitometer also measured the animal’s heart
rate (HR) and arterial oxygen saturation, which were recorded
and used to assess animal condition throughout the experiment.
TR-NIRS measurements were acquired with the emission and
detection probes positioned transversely across the rat ankle
joint on the contralateral paw (Fig. 2). Each joint BF measure-
ment was started by acquiring 10 s of data before a bolus of ICG
solution (0.2 mg/kg) was injected into the rat tail vein. For each
BF measurement, we acquired 400 DTOFs over 120 s to obtain
the tissue ICG concentration curve. On every measurement
day, joint BF was measured on both sides of the animal (i.e.,
right and left ankles); measurements were repeated twice to
mitigate potential unsuccessful measurements. Typical reasons
for unsuccessful measurements included data loss due to DDG
instrument failure, failed ICG injections due to poor catheter
placement, and loss of probe contact (both DDG and TR-NIRS)
during acquisition.
2.4 Data Analysis
The TR-NIRS measurements were analyzed using an in-house
software developed in MATLAB 2017a (The MathWorks Inc.,
Natick, Massachusetts, 2017). For each measurement, the differ-
ence in mean photon time-of-flight (hti) between the DTOFs
acquired prior to contrast introduction (India Ink for phantom
experiments; ICG injection for animal experiments) and the sys-
tem’s IRF was used to compute the optical pathlength p
EQ-TARGET;temp:intralink-;e001;326;408 ¼ c
n
ðhtiDTOF − htiIRFÞ: (1)
In Eq. (1), c is the speed of light in vacuum, and n is the
refractive index of tissue (n ¼ 1.4). The optical pathlength was
then used, in combination with the modified Beer–Lambert








In Eq. (2), IðtÞ and I0 are the detected light intensities after
and prior to introduction of the contrast agent, respectively. Note
that light intensities were computed as the sum of the total num-
ber of photons in each DTOF and that, for animal experiments,
changes in pathlength due to ICG injection were deemed neg-
ligible as discussed in Sec. 4. For phantom experiments, the
measured Δμa were compared with expectedΔμa for validation.
The expected Δμa were computed using Eq. (3). The molar
absorption coefficient of the ink (εa;ink) was calculated by deter-
mining the molar extinction coefficient εe;ink from a transmis-
sion measurement through India ink of known dilution and
multiplying it by the ratio εa;inkεe;ink ¼ 0.885
38 as suggested by
Spinelli et al:39
EQ-TARGET;temp:intralink-;e003;326;126Δμa;expected ¼ lnð10Þεa;inkΔc; εa;ink ¼ 0.885εe;ink: (3)
For joint measurements, it was noted that the geometry of
the joint, along with its expected structural changes during dis-
ease progression, substantially complicates the use of typical
Fig. 1 Experimental timeline. Baseline measurements (B1 to B3) were acquired within a 10-day period
before and on the day of arthritis induction in the experimental group (day 0). Starting on day 20, animals
in the experimental group were treated with the DMARD Enbrel® (etanercept) every 5 days.
Fig. 2 Image of TR-NIRS probe placement on a rat ankle for joint BF
measurement. A dye densitometer, placed on the contralateral paw,
was used to measure the time-dependent arterial concentration of the
BF tracer (ICG) while TR-NIRS probes were used to measure its tis-
sue concentration.
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analytical solutions of light propagation in tissue and fitting
approaches to determine optical properties (see Sec. 4 for
detailed discussion). Instead, use of the modified Beer–Lambert
Law to compute changes in absorption provides a robust method
that is immune to the challenges posed by the joint morphology.
Furthermore, the measured ΔμaðtÞ was converted into an ICG
tissue concentration curve using
EQ-TARGET;temp:intralink-;e004;63;675 ðtÞ ¼ ΔμaðtÞ
lnð10Þ · εICG
; (4)
where QðtÞ is the time-dependent ICG concentration in the
ankle joint, and εICG is the extinction coefficient of ICG at
805 nm.40 The measured tissue and arterial ICG concentration
curves were subsequently used to compute joint BF, using a pre-
viously reported deconvolution algorithm.41 Note that this
method of computing BF has been previously tested and vali-
dated using phantom and animal experiments.42,43 As mentioned
in Sec. 2.3, four perfusion measurements (two per ankle joint)
were obtained for each animal in order to account for potentially
unsuccessful data collection. If both repeat measurements from
one ankle were available, the BF value for that ankle on that day
was calculated as the mean of the two measurements. It is note-
worthy that in ∼10% of cases, one out of the two repeat mea-
surements was missing and only the nonmissing value was used.
2.5 Statistical Analysis
Statistical analysis was conducted using SPSS Statistics 25
(IBM Corp., Armonk, New York, 2017), and power analysis
was performed using G*Power software.44 For the phantom
experiments, agreement between expected and measured
changes in μa was investigated using linear regression.
Regression analysis was performed using a y-intercept fixed
at 0 with the assumption that Δμa;observed ¼ Δμa;expected ¼ 0
prior to the addition of any India ink. Prior to analysis, regres-
sion assumptions of linearity and homoscedasticity were
confirmed. For the linearity assumption, a visual inspection
of scatter plots of raw observed versus expected values was used
to confirm a linear relationship between the two variables. Data
homoscedasticity was confirmed by generating scatter plots of
residuals versus values predicted by the regression model and
visual confirmation of consistent variance of the residuals for
all predicted values. Furthermore, assumption of normality in
the dataset was confirmed using the Shapiro–Wilk test.
For the in vivo experiments, statistical analysis was only con-
ducted for timepoints that contained data from all animals, to
account for animals reaching HEP before study completion.
Though this approach limited the scope of the statistical analy-
sis, it was necessary in order to avoid any potential survivorship
bias within the dataset. A three-way repeated measures analysis
of variance (ANOVA) was conducted with time and measure-
ment side (i.e., left or right) as the within-subjects variables, and
subject group as the between-subjects variable (i.e., control or
experimental group). Prior to analysis, normality of the depen-
dent variable and sphericity were confirmed, using the Shapiro–
Wilk test and Mauchly’s test of sphericity, respectively, to
ensure no assumptions inherent to ANOVA were violated. In
addition, visual inspection of boxplots and histograms of BF
data within each group revealed no significant outliers. Upon
discovering a significant effect, differences were uncovered
using a post-hoc Tukey’s honest significant difference test to
account for multiple comparisons. A post-hoc test in G*Power
was then used to assess the power of the findings using an effect
size equal to the partial η2 value determined from the ANOVA.
The potentially confounding effects of HR on joint BF were
investigated using correlation analysis. Since joint BF could be
affected by arthritis induction and DMARD treatment, as well as
other temporal factors, the effect of HR on joint BF could only
be isolated on a per day basis. Thus, for timepoints with no miss-
ing data, each animal’s raw daily BF measurements were corre-
lated with their corresponding HR to generate a correlation
coefficient between BF and HR for each day. Since each corre-
lation coefficient was derived using only four comparisons (one
for each raw measurement), the resulting coefficients were
prone to error and difficult to interpret in isolation; instead, all
obtained correlation coefficients were averaged with the
assumption that the presence of an underlying trend in the data
would skew the average correlation coefficient.
3 Results
3.1 Phantom Experiments
A simple linear regression with the y-intercept set to 0 (see
Sec. 2.5 for details) was conducted to compare Δμa measured
Fig. 3 Comparison of expected and measured changes (mean SD)
in the absorption coefficient of a tissue-mimicking solution (0.8%
Intralipid) caused by incremental addition of India Ink. One hundred
measurements were acquired using the time-resolved NIR spectros-
copy system, and absorption coefficients were computed using the
modified Beer–Lambert Law. Note that absorption changesmeasured
during subsequent animal experiments were within this range.
Fig. 4 Arterial and tissue ICG concentration curves measured by the
dye densitometer and the TR-NIRS system, respectively. ICG was
injected into the rat’s tail vein at the 10-s mark.
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in tissue-mimicking solution with the expected Δμa due to India
ink addition. There was a significant linear relationship between
measured and expected Δμa [Fð1;9Þ ¼ 5773, p < 0.05], and a
strong relationship between the variables (R2 ¼ 0.99) with a
slope of 0.96 within the tested 0.005 to 0.040 cm−1 absorption
range (Fig. 3).
3.2 Animal Experiments
Figure 4 shows typical arterial and tissue ICG concentration
curves measured during an animal experiment. The dynamic
inflow and washout of the tracer can be clearly identified on
both curves, with the tissue curve showing a slower rise and
subsequent clearing of ICG compared with the arterial curve.
The results of the statistical analysis from the first day of the
baseline period (B1) to day 15 are summarized in Table 1. In all
cases, the BF data were not significantly different from a normal
distribution (p ¼ ns; ns, not significant) and did not violate the
assumption of sphericity (p ¼ ns). Only time and group were
found to have a significant main effect on joint BF (Table 1)
with effect sizes of partial η2 ¼ :400 and η2 ¼ :365, respec-
tively. These effects were interpreted as follows: BF increased
over time regardless of group assignment, and experimental
group BF was higher than control group BF regardless of meas-
urement time. Figures 5(a) and 5(b) show the data relevant to the
statistically significant effects denoted in Table 1: a BF time
course averaged over measurement side and group, and group
BF values averaged over time and measurement side. As seen in
Fig. 5(a), a post-hoc Tukey test for the effect of time on ankle
joint BF revealed a significant difference between BF on the first
day of baseline (B1) and BF on day 10 at the p < 0.05 level. In
addition, since statistical analysis revealed that measurement
side was not implicated in any interaction and did not have a
significant main effect on BF (Table 1), time courses for each
group averaged over measurement side are presented in Fig. 5(c)
to facilitate interpretation of the uncovered main effects. We
Table 1 Summary of three-way repeated measures ANOVA with
time andmeasurement side as the within-subject variables, and group
as the between-subjects variable. Analysis was conducted on data
from the first day of the baseline period (B1) to day 15 postinduction
of arthritis.
Variable(s)a F -statistic p-Valueb
timeagroupaside F ð5;50Þ ¼ 0.149 p ¼ ns
timeaside F ð5;50Þ ¼ 0.659 p ¼ ns
timeagroup F ð5;50Þ ¼ 1.773 p ¼ ns
groupaside F ð1;10Þ ¼ 0.135 p ¼ ns
Time F ð5;50Þ ¼ 6.670 p < 0.05
Group F ð1;10Þ ¼ 5.736 p < 0.05
side F ð1;10Þ ¼ 0.129 p ¼ ns
aInteraction between multiple variables
bns: not significant
Fig. 5 (a) BF (95% confidence interval) for time courses averaged by group and measurement side,
and (b) boxplots of BF for each group averaged over time and measurement side. Asterisks indicate a
significant difference at the p < 0.05 level between (a) two timepoints or (b) two groups. To facilitate
interpretation of main effects, BF (95% confidence interval) time courses for each group averaged over
measurement side are shown in (c). Time courses (a) and (c) show three baseline measurements (B1 to
B3; gray), followed by threemeasurements postarthritis induction in the experimental group (after B3: day
0; orange). Note that, to avoid survivorship bias, statistical analysis was only conducted on timepoints
that included all animals in each group; thus, data from the treatment phase are not shown.
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note that the primary effect of interest in this work was the pres-
ence of a two-way interaction between time and group, which
would have manifested as a significant difference between the
time courses in Fig. 5(c). The presence of this effect would have
been interpreted as a difference in joint BF between the exper-
imental and control group over time. To further investigate the
lack of this effect (Table 1), post-hoc power analysis was calcu-
lated for the two-way interaction between time and group using
an effect size of partial η2 ¼ 0.151 and yielded a power of 0.21.
Confounding effects of HR on measured joint BF values
were investigated by correlating raw BF measurements with
their corresponding HR and averaging across all animals and
days as described in Sec. 2.5. This analysis revealed a weak
positive correlation (r ¼ 0.1370) between HR and BF
measurements.
To further investigate the variations in joint BF, longitudinal
measurements from each individual rat were examined (Fig. 6);
time courses for raw data as well as data averaged across meas-
urement side are presented. Consistently elevated joint BF levels
throughout the pretreatment phase were only observed for rats
1 and 2; these animals had the highest incidence of ankle BF
above the typical baseline threshold of ∼15 mL∕min ∕100 g.
For four out of eight rats in the experimental group, joint BF
on day 5 was higher than their typical baseline values. In the
control group, joint BF on day 10 for was higher than typical
baseline values for three out of four rats. Rats 3 and 4 were the
only individuals in the experimental group who completed the
entire study period; these rats also showed very minimal
variation in their joint BF compared with other rats in their
group, and their BF times courses are generally more similar
to those of the rats in the control group. In contrast, for rats
1 and 2 joint BF decreased once treatment was initiated; how-
ever, only a few treatment timepoints are available since these
rats reached HEP quickly. Looking at individual side measure-
ments, there is no clear trend in the inconsistency between
measurement sides across animals. For the experimental
group, average BF time courses among rats are more similar
within each cohort than between cohorts. This similarity is also
present in the occurrence of first symptoms and reaching of
HEP (Fig. 6).
4 Discussion
This work sought to investigate whether joint BF, as measured
with DCE TR-NIRS, could track longitudinal changes in joint
inflammation during disease induction and DMARD treatment
in the AIA rat model of RA. AIAwas the first-described animal
model of RA and remains widely used for preclinical assessment
of RA treatments.45 The model is typically characterized by
rapid onset (e.g., 10 days postinjection) and progression of pol-
yarticular arthritis; however, the inflammation tends to subside
after a month of disease activity. While the AIA rat model does
not exhibit the chronic disease progression characteristic of
human RA, which takes place over months, it shares many
of the relevant biological features, such as swelling, joint
destruction, cell infiltration, and T-cell dependence. As well,
treatment with etanercept—a common biologic drug that is
Fig. 6 Scatter plots of individual BF values (mL/min/100 g) for each rat; average BF values are shown as
black markers, whereas right and left ankle measurements are indicated using red and blue markers,
respectively. Time courses show three baseline measurements (B1 to B3; gray), followed by measure-
ments post-arthritis induction in the experimental group (after B3: day 0; orange) and after DMARD treat-
ment was started (days 20 to 40; blue). Experimental and control group data are enclosed by red and blue
borders, respectively. For the experimental group, HEP and appearance of first symptoms are indicated
by solid and dashed vertical lines. Rats in the experimental group were studied in cohorts of 2 while those
in the control group were studied in one cohort of 4; experimental group data are subdivided by black
lines to delineate cohorts. Cohort numbers for both groups are indicated at the top right (C1 to C5).
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currently used to treat RA patients—is known to be active in this
model and has been associated with slight reductions in arthritic
and radiographic scores.36,46 It is important to note that rats tend
to develop antibodies against etanercept; thus, when considering
the difference in body weight, response to the drug is limited to
higher treatment doses (e.g., 4 to 10 mg every 3 to 5 days)21,46
than what is typically used in RA patients (50 mg weekly).
For proper quantification of joint BF, DCE TR-NIRS relies
on an accurate measurement of the dynamic μa changes in a
tissue bed following an ICG bolus injection. These measure-
ments can be used to compute a tissue ICG concentration curve,
which can then be combined with an arterial ICG concentration
curve to calculate BF. As such, we conducted tissue-mimicking
phantom experiments to ensure that our TR-NIRS system could
accurately measure changes in μa. Figure 3 shows a strong linear
relationship (R2 ¼ 0.99) with a slope of 0.96 between expected
and measured μa changes in a tissue-mimicking phantom whose
absorption coefficient was modulated using various concentra-
tions of India Ink; these results confirmed our system’s ability
to quantify static changes in μa. Next, the ability of the TR-
NIRS system to track dynamic changes in absorption was con-
firmed through preliminary animal experiments during which
representative arterial and tissue ICG concentration curves were
obtained. Tissue ICG concentrations were ∼100 times lower
than the concentrations of the tracer in arterial blood (Fig. 4),
which was similar to what we previously reported for tissue con-
centration values in the rabbit knee joint.35
Following system validation, experiments were conducted in
12 rats: four rats in the study’s control group and eight rats in the
AIA experimental group. To account for potential injection
effects, rats in the control group received saline injections to
match any injections administered to the experimental group.
Due to the severity of the AIA model, 50% of rats in the exper-
imental group reached HEP before day 20 postinduction of
arthritis. Thus, to avoid survivorship bias, we limited the tem-
poral scope of our subsequent statistical analysis to timepoints
that contained data from all animals, i.e., all baseline timepoints
and the first three timepoints of the pretreatment phase. The only
significant effects found in this study were that both time and
group had a significant main effect on joint BF with effect sizes
of η2 ¼ 0.400 and η2 ¼ 0.365, respectively [Figs. 5(a) and 5(b)].
Interestingly, the implication of the main effect denoted in
Fig. 5(b) is that BF differed between rats in both groups regard-
less of when it was measured (i.e., even at baseline). To further
investigate this possibility, we compared mean BF time courses
of both groups along with their 95% confidence intervals
[Fig. 5(c)]; since measurement side did not have a significant
effect on BF, we averaged time courses across both ankles to
facilitate data interpretation. First, BF appears consistent
between both groups and among the baseline timepoints
[Fig. 5(c)]; this is an important result as it confirms the ability
of our DCE TR-NIRS technique to reliably quantify joint BF.
Second, once arthritis is induced (pretreatment), BF in the
experimental group is substantially higher than in the control
group on day 5 after which BF in the control group rises to
match that of the experimental group. These trends in Fig. 5(c)
are consistent with the significant effect seen in Fig. 5(a);
regardless of AIA, joint BF changes as the study period pro-
gresses. Furthermore, Fig. 5(c) suggests that the significant
effect described by Fig. 5(b) is largely driven by the discrepancy
in BF between both groups on day 5. Nevertheless, this single
discrepancy was not substantial enough for the time courses in
both groups to be statistically different from one another (i.e., no
significant interaction between time and group).
As mentioned in Sec. 1, it is well established that chronic
inflammation, which is a key feature of RA, leads to the devel-
opment of hypoxic regions within the synovium15,17 and that the
presence of hypoxia acts as a potent signal for angiogenesis17
and increased tissue BF.19,20 Based on this known pathophysi-
ology of inflammatory arthritis and the results from our previous
study in a rabbit model of inflammatory arthritis,35 we expected
to find an interaction between time and group in this study. More
specifically, we anticipated an increase in joint BF in the exper-
imental group compared with the control group during the pre-
treatment phase.
One possible reason that this study did not find a significant
difference between control and experimental group time courses
was the introduction of measurement error due to the variation in
animal HR during different BF measurements. However, only a
very weak correlation (r ¼ 0.1370) was noted between HR and
joint BF, suggesting that the potentially confounding effect of
varying HR throughout an experiment had a negligible effect
on the BF results. Another reason could be the relatively small
sample size. Based on the effect size observed here for the two-
way interaction between time and group (partial η2 ¼ 0.151),
post-hoc power analysis revealed that, in regards to this two-way
interaction, our study only had a power of 0.21. To reach a
power of 0.8 with the aforementioned effect size, our study
would require a sample size of 74; this is a notable difference
from the large effect size we previously measured in an inflam-
matory monoarthritis rabbit model,35 where only four subjects
were needed to detect a statistically significant difference
between control and inflamed joints at the p < 0.05 level with
a power of 0.8. In particular, this discrepancy between both stud-
ies highlights the challenge of modeling human disease with ani-
mal models.
Aside from differentiating between groups during the pre-
treatment phase, this study sought to investigate whether treat-
ment with etanercept affects joint BF in the AIA model
postinduction of arthritis. Since etanercept is known to be active
in this model of arthritis,36,46 we expected to see decreased joint
BF in response to etanercept treatment. However, because no
statistical analysis could be performed for timepoints in the
treatment phase, we compared treatment response between con-
trol and experimental group rats on a case-by-case basis (Fig. 6).
Only rats from cohorts 1 and 2 progressed into the treatment
phase, and only rats from cohort 1 showed evidence of BF
decrease in response to treatment. In particular, their BF dropped
from the elevated pretreatment values on days 15 and 20 to val-
ues similar to cohort 2 and control rats on days 25 and 30. Rats
in cohort 2 did not have elevated pretreatment BF values, and
their BF remained relatively constant throughout the study. In
fact, aside from a slight elevation in BF in rat 3 on day 5, the
time courses of the rats in cohort 2 looked quite similar to those
of the control group. Consultation of recorded animal well-
being metrics revealed that rats 3 and 4 had the latest appearance
of first symptoms (Fig. 6) and, while both rats exhibited some
paw swelling, they did not have the gait issues that were typi-
cally seen in the other cohorts. Thus, the relatively mild disease
induction in cohort 2 rats may have played some role in making
it difficult to distinguish between them and control group rats on
the basis of joint BF. Importantly, the approach that is typically
reported in the literature is to administer treatment on the
first day of inflammatory symptoms. In contrast, our study was
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designed so that treatment was only administered at a set time-
point regardless of first symptom appearance. Since some vari-
ability in disease progression is expected and was observed
between rats, it is possible that experimental group rats received
treatment while in a different state of disease progression, which
may have confounded the treatment phase results. Due to these
factors as well as the small experimental group sample size
available from the treatment phase, the conclusions regarding
the relationship between joint BF and DMARD treatment
response remain limited.
We also examined the pretreatment phase of Fig. 6 for any
consistent differences between the experimental and control
groups. Four out of eight rats in the experimental group showed
BF increases on day 5, whereas increases from baseline only
occurred on day 10 in three out of four rats in the control group;
this is consistent with the BF difference on day 5, as shown in
Fig. 5(c). A striking observation from Fig. 6 was that, for the
entire study period, time courses among rats within the same
cohort were more similar than rats from different cohorts.
Figure 6 also revealed that rats within the same cohort experi-
enced first symptoms within a day of each other while first
symptom occurrence had a standard deviation of 2.20 days
when all cohorts were combined. Together, these observations
suggest that rats in the same cohort had similar disease progres-
sion and that the heterogeneity in the response to arthritis induc-
tion between cohorts may have had an important influence on
the BF time courses. This observation is further confirmed by
the temporal consistency between first symptom appearance and
HEP within each cohort. To further investigate this possibility,
we used SPSS Statistics 25 to perform a hierarchical cluster
analysis on the experimental group’s BF values from the first
day of the baseline period (B1) to day 15 postinduction of dis-
ease. Since no outliers were present in the dataset, Ward’s
method was used as the cluster method and squared Euclidean
distance as the similarity metric; the elbow method was sub-
sequently used to identify the optimal number of clusters.47
The analysis revealed that four distinct clusters were present
in the data: one for each cohort in the experimental group.
To confirm the stability of the solution, we randomized the order
of the data and reran the analysis three times. In addition, we
also performed k-means clustering on the original dataset and
assumed that four clusters were present in the data. For all analy-
ses, it was determined that the same four clusters were present in
the data, with each cluster corresponding to our original cohort
assignments. This provides further evidence that a main source
of inconsistency in the study is that animals were divided into
small cohorts whose arthritis was induced using four different
Mycobacterium butyricum solutions. Though every effort was
taken to ensure that all solutions were prepared using the same
protocol, it is possible that slight variations in injected solution
volume or preparation (e.g., mixing of bacteria with Freund’s
adjuvant) contributed to varied disease induction among the
experimental group.
As shown in this study, temporal variability in intersubject
disease and treatment response made it difficult to interpret the
link between changes in BF and disease severity. Cases like this
benefit particularly from the ability of DCE TR-NIRS to reliably
quantify tissue perfusion in absolute units, which makes it pos-
sible to compare a single subject’s values over a long range of
timepoints to uncover potential physiological relationships. It is
important to note that other optical techniques, such as diffuse
correlation spectroscopy (DCS), can noninvasively monitor
tissue perfusion;48–50 for example, DCS generally provides a
BF index whose proportionality to absolute BF is a function of
tissue optical properties and tissue geometry. Importantly, RA
progression is associated with synovial lining hypertrophy,
typically leading to bone resorption, membrane inflammation,
edema, and other general morphological changes to the joint
tissue, which makes modeling the joint geometry quite
challenging.45 Considering that these changes vary from subject
to subject, accurate quantification of tissue optical properties
during disease progression and treatment with DCS could be
very difficult. Furthermore, failing to account for these changes
would likely confound the relationship between BF indices mea-
sured at different timepoints. There are systems that combine
DCS with TR-NIRS or frequency-domain NIRS to make it pos-
sible to quantify the necessary optical properties for continuous
DCS measurement on a day-by-day basis;48,51,52 however, these
approaches still typically rely on the use of analytical solutions
to the diffusion equation for simple tissue geometries (e.g., slab
geometry). As mentioned in Sec. 2.4, a key advantage of our
DCE TR-NIRS technique is that it only requires the ability
to quantify changes in absorption to measure joint BF. This cir-
cumvents the challenge of needing an analytical solution to the
diffusion equation for a joint structure with a complex shape that
changes both in time and across subjects and is not well approxi-
mated by regular geometrical shapes.
While DCE TR-NIRS has unique advantages that make it
suitable for longitudinal joint BF monitoring, a potential source
of error while using this technique is the occurrence of dynamic
changes in optical pathlength caused by changes in absorption
due to the passage of ICG through the joint. To address this, we
estimated the change in optical pathlength for five datasets and
found that, on average, pathlength varied by0.5% over a 120-s
measurement period. When these differences were propagated
forward in the analysis, they only resulted in a 1% change
in recovered BF values. Since these changes are negligible, for
computational efficiency, p was estimated using the mean path-
length measured prior to ICG injection. Another limitation of
DCE TR-NIRS is that it requires the use of a contrast agent
(e.g., ICG), which may limit clinical translation. However, it has
been previously shown that changes in tissue oxy- and deoxy-
hemoglobin concentrations in muscle following venous occlu-
sion can be used to quantify BF in lieu of a contrast agent.53
While the ability of the latter method to quantify joint perfusion
has yet to be tested, it offers an interesting alternative that could
be readily implemented with TR-NIRS instrumentation and
should be an area of future research.
Despite the advantages of the DCE TR-NIRS technique, the
small sample size of this exploratory work, issues with animal
survivorship, and sources of error linked to disease hetero-
geneity among the experimental group limit this study’s conclu-
sions regarding the link between BF, arthritis induction, and
DMARD treatment response in the AIA model. Overall, we
found the use of the AIA model in a continuous, longitudinal
study design challenging due to the severe and rapid onset of
the disease, which often occurred in the 5-day periods between
subsequent BF measurements. We also conducted a subset of
experiments to investigate mycobacterium dose and disease
severity but could not determine a reliable dose for inducing
slower and milder arthritic progression. Considering the mis-
match between this relatively rapid disease progression and the
relatively low overarching temporal resolution of our data (i.e.,
one measurement every 5 days), our time courses may have
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missed otherwise important variations in BF and disease activ-
ity. While the temporal frequency of our BF measurements was
part of the original study design, which was formulated based
on results from our previous study,35 it was ultimately a limita-
tion of the study presented here and should be amended in future
work. The authors also acknowledge the potentially con-
founding effect of anesthesia induced by isoflurane on BF in
rodents.54,55 Though anesthetic concentrations were tightly
managed to consistent levels during experiments, future work
may benefit from investigating whether varying isoflurane con-
centrations or using other anesthetics such as ketamine has an
effect on joint perfusion. Future work would also benefit from
exploring longitudinal BF changes in milder models of RAwith
slower symptom onset, such as pristane-induced arthritis,56 to
allow a more robust investigation of the relationship between
DMARD treatment and joint BF.
5 Conclusion
In this work, we used our quantitative joint perfusion technique
(DCE TR-NIRS) to monitor joint BF in a longitudinal rat model
of RA. Joint BF was measured in each animal’s left and right
ankles before treatment (pretreatment phase) and after treatment
with the DMARD etanercept (treatment phase) in an experimen-
tal group of eight rats with AIA. Four additional rats served as
controls throughout the study. Time and group had separate sig-
nificant effects on joint BF; however, there was no significant
interaction between time and group despite a large difference in
average BF values on day 5. Measurement side did not have a
significant effect on joint BF. Statistical analysis of the treatment
phase was limited since 50% of the animals reached HEPs
before starting treatment. Comparison of individual animal time
courses between the experimental and control group revealed no
consistent trend in treatment response; effects may have been
masked by heterogeneous disease response to AIA in the exper-
imental group. Future work will focus on exploring longitudinal
BF changes in milder models of RAwith slower symptom onset
to allow a more robust investigation of the relationship between
DMARD treatment and joint BF.
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